is glp-1 patented pharmaindustry #glp1 #patentcliff #obesitytreatment #diabetescare #indianpharma #biologics The recent excitement about the

Low carbs

Importantly, clinical evidence in humans remains extremely limited, meaning that promising animal results should be interpreted cautiously until validated in well-controlled trials

Currently, a major gap in the field that applies here relates to the need for a diagnostic biomarker in humans that correlates with pre-neoplastic disease progression (e.g., indicating a high grade PanIN)

This provides your cells with a steady supply of the "master antioxidant" and allows your body to integrate it into its natural cycles of repair and protection

Source: Hwang, et al JAMA Health Forum March 14, 2025 Researchers from the University of Chicago modeled the clinical and financial impact of anti-obesity medications: Zepbound (tirzepatide), Wegovy (semaglutide), and two oral generic drug combinations, phentermine-topiramate and naltrexone-bupropion

Modern data confirm GLP-1 agonists are not linked to pancreatitis